Tests a diet plan for people newly diagnosed with multiple myeloma
Tests whether a dietary plan affects treatment and quality of life in adults with myeloma.
Plain-language title generated from the registry record
Registry title: A Dietary Study for People With Multiple Myeloma
Key facts
- Where
- Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Uniondale, United StatesSee the 7 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed multiple myeloma who are about to receive 4 cycles of DRVd chemotherapy and who eat little dietary fiber.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Newly diagnosed multiple myeloma with bone marrow involvement, confirmed by bone marrow biopsy
- Earlier treatment
- Must be planned for four 28-day cycles of daratumumab (or isatuximab), lenalidomide, bortezomib and dexamethasone (DRVd), with all 4 drugs started by C2D1. Up to one cycle of cyclophosphamide and/or bortezomib with dexamethasone is allowed before. Prior combination infusion chemotherapy such as VDPACE or DCEP is not allowed.
- Biomarker or test result
- Cytogenetic testing (FISH, SNP array or genomic sequencing) and blood myeloma markers are needed to confirm the diagnosis. Daily diet must contain less than 30 grams of fiber.
Main reasons for not taking part
- Myeloma in the brain or spinal fluid (leptomeningeal/CNS involvement)
- BMI of 19 kg/m2 or lower
- Already eating a whole food plant-based diet in the last 3 months
- Severe allergy to legumes, peanuts or tree nuts
- Another trial or weight loss or diet program that requires different treatment or a specific diet
Read by machine on 9 November 2026.
Where in United States
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge, United StatesTaking people
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack, United StatesTaking people
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison, United StatesTaking people
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, United StatesTaking people
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, United StatesTaking people
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesTaking people
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT07226609
- Record updated
- 5 May 2026
- Original description
The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd). The researchers will measure quality of life by having participants complete questionnaires. The study will investigate the effects of diet on quality of life, treatment response, and other disease, microbiome, and immune markers.Read full original descriptionShow less
A Decentralized Randomized Dietary Trial in Newly Diagnosed Multiple Myeloma - NUTRIVENTION5
The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd). The researchers will measure quality of life by having participants complete questionnaires. The study will investigate the effects of diet on quality of life, treatment response, and other disease, microbiome, and immune markers.
Inclusion: Newly diagnosed multiple myeloma; Patients must have pathologically confirmed multiple myeloma on bone marrow biopsy with cytogenetics via Florescence in Situ Hybridization (FISH) or SNP array or genomic sequencing report and evaluation of blood myeloma markers (quantitative immunoglobulins, free light chains, serum protein electrophoresis and immunofixation); Age ≥ 18 years; Bone marrow involvement; Planned for four 28-day cycles of daratumumab (or isatuximab), lenalidomide, bortezomib, dexamethasone (or any other steroid) (DRVd) induction chemotherapy (with once weekly bortezomib day 1, 8, 15 and lenalidomide 21/28 days); All 4 planned drugs initiated by C2D1; Must enroll before C1D21 of induction chemotherapy as study intervention starts at C2D1; Treatment at a site where treating oncologist has capability and plan to send for bone marrow MRD negativity by next generation sequencing at end of 4 cycles (EOI). To be confirmed with local oncologist at enrollment; Treatment at MSK or at a site that uses EPIC for electronic medical records and willing to share records with MSK through EPIC's Care Everywhere or through MSK's shared care network; Enrollment on another trial that allows for 4 cycles of 28-day DRVd is acceptable; Prior dexamethasone treatment is eligible; Patients who have received up to one cycle of cyclophosphamide and/or bortezomib with dexamethasone for disease control are eligible; Able to complete study procedures and visits; Patients on GLP-1 drugs are eligible if it has been started at least 3 months prior to C2D1 DRVd or if it has been started more recently for diabetes mellitus control but not weight loss. If it is medically indicated and started for diabetes mellitus control while on trial they will not be removed/excluded from trial; Participant or caregiver must be able to complete surveys; Baseline 24-hour dietary recall must consume <30 grams dietary fiber per day to be eligible; Patients that already follow a minimally processed (whole food) plant-based diet in the last 3 months are not eligible (ovo-lacto-vegetarian or processed junk food vegan diets are eligible).
Exclusion: Prior cycles of combination cytotoxic infusion chemotherapy such as VDPACE or DCEP are not eligible; Enrollment onto concurrent therapeutic study that requires patient receives treatment other than 4 cycles of DRVd induction as described above; Concurrent weight loss or dietary programs will be ineligible if require a specific diet or weight loss supplements; Severe allergy to any legume (such as anaphylactic shock) or allergies to multiple legumes or if cross-contamination is a risk are not eligible; Severe allergies such as anaphylactic shock to peanuts and/or tree nuts, such as cashews are not eligible; Leptomeningeal/CNS involvement; Patients with BMI ≤19 kg/m2 are excluded; If in the opinion of the investigator there maybe any concerns regarding the ability of the patient to complete the study safely or any contraindications; Plan for prolonged travel during the study that would preclude adherence to prescribed diet. Willingness to comply during travel is not an exclusion.